30.81
Schlusskurs vom Vortag:
$30.62
Offen:
$30.14
24-Stunden-Volumen:
662.06K
Relative Volume:
0.45
Marktkapitalisierung:
$3.71B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-10.66
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+6.35%
1M Leistung:
+4.62%
6M Leistung:
-28.76%
1J Leistung:
+4.02%
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RNA
Avidity Biosciences Inc
|
30.81 | 3.49B | 10.12M | -280.49M | -188.51M | -2.89 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-13 | Eingeleitet | Citigroup | Buy |
2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-09-24 | Eingeleitet | Goldman | Buy |
2024-08-28 | Eingeleitet | Barclays | Overweight |
2024-05-03 | Eingeleitet | BofA Securities | Buy |
2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
2021-06-17 | Eingeleitet | Needham | Buy |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2020-07-07 | Eingeleitet | Cowen | Outperform |
2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences Expands Team with $2.2M Stock Package: 16 New Hires Signal Growth - Stock Titan
When (RNA) Moves Investors should Listen - news.stocktradersdaily.com
Avidity Biosciences Reports Q1 2025 Earnings - TipRanks
Transcript : Avidity Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Avidity Biosciences to Participate in Upcoming Investor Conference - Kilgore News Herald
Avidity Biosciences (RNA) Target Price Lowered by HC Wainwright & Co. | RNA Stock News - GuruFocus
Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus
Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Avidity Biosciences (RNA) Receives Buy Rating from Chardan Capital | RNA Stock News - GuruFocus
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
12 Analysts Assess Avidity Biosciences: What You Need To Know - Benzinga
RNA Therapeutics Pioneer Avidity Biosciences Takes Stage at Major Bank of America Healthcare Conference - Stock Titan
(RNA) Investment Report - news.stocktradersdaily.com
Avidity Biosciences chief program officer sells $190k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief program officer sells $190k in stock - Investing.com Australia
Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada
Avidity Biosciences appoints Deloitte as new auditor - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt
Avidity’s del-desiran for DM1 named orphan drug in Japan - Muscular Dystrophy News
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga
Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider
Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com
Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India
Japan grants Avidity's DM1 drug Orphan status - Investing.com
Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Avidity Biosciences chief program officer sells shares worth $206,799 - MSN
Avidity Biosciences CFO sells $93,985 in stock - MSN
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq
When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com
Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com
Exclusive Look: Avidity Biosciences Reveals Latest Strategy at Needham Healthcare Conference - Stock Titan
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):